Two cancer drugs by AstraZeneca, lung cancer treatment Imfinzi and tremelimumab, have both received the FDA's orphan drug designation. Both drugs are currently being tested as a combo therapy in patients with liver cancer in the company's late-stage study dubbed Himalaya.
2 AZ cancer drugs granted orphan status from FDA
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.